Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Galapagos Knocked By Knee Osteoarthritis Fail

Servier-Partnered Drug Shows No Activity in Phase II

Executive Summary

Still reeling from the FDA rejection of its JAK inhibitor filgotinib for rheumatoid arthritis, the Belgium-headquartered biotech's ADAMTS-5 inhibitor developed with France's Servier is sunk after failing to significantly reduce cartilage loss compared with placebo in an OA trial.

You may also be interested in...



End Of An Era As Galapagos CEO Van De Stolpe Retires

Some 22 years after founding what was one of the biggest success stories in Europe's biotech sector before a recent series of setbacks in the clinic struck, Onno van de Stolpe has decided to retire as Galapagos CEO and the search has already started for his successor.

Bone Has Tough Path Forward After Phase III Knee Osteoarthritis Fail

The company said the study of JTA-004 failed to meet its primary and key secondary endpoints, though a post-hoc analysis indicated activity in a patient subset.

Osteoarthritis Drug Development: ‘Clinically Meaningful Endpoints’ Remain Elusive

US FDA is ‘willing to look at anything’ but sponsors need to demonstrate an effect on pain as drug development challenges remain. Accompanying chart describes 32 drugs in Phase II and Phase III clinical trials and one with a pending biologics license application.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel